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Abstract
Background: Long-term immunosuppression is often required in myasthenia gravis (MG). There are no published
trials using methotrexate (MTX) in MG. The steroid-sparing efficacy of azathioprine (AZA) has been demonstrated
after 18-months of starting therapy. However, AZA is considered expensive in Africa. We evaluated the steroid-
sparing efficacy of MTX (17.5 mg weekly) compared with AZA (2.5 mg/kg daily) in subjects recently diagnosed with
generalized MG by assessing their average monthly prednisone requirements.
Methods: The primary outcome was the average daily prednisone requirement by month between the two
groups. Prednisone was given at the lowest dose to manage MG symptoms and adjusted as required according to
protocol. Single-blinded assessments were performed 3-monthly for 2-years to determine the quantitative MG
score and the MG activities of daily living score in order to determine those with minimal manifestations of MG.
Results: Thirty-one subjects (AZA n = 15; MTX n = 16) satisfied the inclusion criteria but only 24 were randomized.
Baseline characteristics were similar. There was no difference between the AZA- and MTX-groups in respect of
prednisone dosing (apart from months 10 and 12), in quantitative MG Score improvement, proportions in sustained
remission, frequencies of MG relapses, or adverse reactions and/or withdrawals. The MTX-group received lower
prednisone doses between month 10 (p = 0.047) and month 12 (p = 0.039). At month 12 the prednisone dose per
kilogram bodyweight in the MTX-group (0.15 mg/kg) was half that of the AZA-group (0.31 mg/kg)(p = 0.019).
Conclusions: This study provides evidence that in patients with generalized MG methotrexate is an effective steroid-
sparing agent 10 months after treatment initiation. Our data suggests that in generalized MG methotrexate has similar
efficacy and tolerability to azathioprine and may be the drug of choice in financially constrained health systems.
Trial registration: SANCTR:DOH-27-0411-2436
Background
Methotrexate (MTX) is a cost-effective immunosuppres-
sant. Although anecdotal reports of its use in myasthenia
gravis (MG) date back several decades, there are no pub-
lished randomized or quasi-randomized trials [1].
Azathioprine (AZA) is considered by most to be the first-
line steroid-sparing immunosuppressant in MG [2] and
data show that it has significant steroid-sparing activity
compared with prednisone alone after 18 months of
treatment [3]. However, AZA is considered an expensive
therapy in the developing world.
The incidence of MG in sub-Saharan Africa is expected
to be similar to that elsewhere in the world were patients
able to access appropriate health care [4]. Despite the
need for cheaper MG therapies in developing countries,
developed countries are investigating more costly alterna-
tives [5]. As MTX is substantially cheaper than AZA it
has the potential for wider availability in Africa. Efficacy
data for MTX in MG is therefore of critical importance.
MTX is used effectively as an immunosuppressant in
target-organ autoimmune disease such as Crohn’s disease
and psoriasis and it is considered the disease modifying
agent of choice in rheumatoid arthritis (RA) [6]. Mertens
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et al. [7] alluded to the efficacy of MTX in generalized
MG decades ago. However, many recent reviews on MG
therapies either do not include MTX as an option [5,8,9]
or only regard this agent as an alternative if other drugs
have failed [10].
MTX is a structural analog of folic acid and exerts an
anti-proliferative effect by metabolic interference with
DNA synthesis. The safety and efficacy of MTX in RA is
well established [6] and studies suggest that MTX may
show earlier efficacy compared with AZA [11]. In RA, sub-
stantial data show that a weekly MTX dose of 17-20 mg
produces an optimal efficacy/toxicity ratio [6,12,13].
The main objective of this study was to determine the
efficacy of MTX as a steroid-sparing agent in subjects who
had recently been diagnosed with generalized MG, and
compare this with the efficacy of AZA. In MG, AZA has
been shown to be an effective steroid-sparer compared to
placebo after a treatment period of 18 months [3]. To
achieve this we performed a 24-month parallel study with
a design similar to that of Palace et al. [3].
Methods
A randomized, single-blind study of AZA and prednisone
as compared to MTX and prednisone was planned to
recruit 60 patients who had recently been diagnosed with
generalized MG. This sample size calculation was based
on the proportion of patients with MG who were steroid-
independent after receiving AZA vs. placebo for a period
of 36 months (AZA-Placebo Δ = 40%) [3] and AZA vs.
MTX at six months in inflammatory bowel disease
(AZA-MTX Δ = 7%) [14], as well as taking into consid-
eration anticipated feasibility and recommendations by
Barohn et al. [15].
To meet the objective of comparing the steroid-spar-
ing effectiveness between AZA and MTX, the primary
outcome was the average prednisone dose required in
each group to achieve and maintain minimal manifesta-
tion status (MMS) over 24 months. The clinical MG
measurements were assessed by blinded assessors and
used to adjust prednisone dosing per protocol, aiming
for MMS as defined by the MGFA (i.e. no symptoms of
limitation of functioning during everyday living even if
some fatiguable weakness was noted on examination)
[16]. The MG activities of daily living (MG-ADL) ques-
tionnaire was used to objectively assess functional status
and subjects in MMS were required to have no MG
symptoms (MG-ADL = 0) [17].
Secondary outcomes included the improvement in
quantitative MG score compared to baseline, frequency
of adverse events and treatment failures in each group.
Treatment failures were defined as: withdrawal from the
study whether due to intolerance of study medication
or uncontrolled MG disease requiring alternative
medications; hospitalization for MG relapse or intrave-
nous antibiotic therapy; and death (all-cause mortality).
Subjects
All patients had newly diagnosed (within the previous
six months) generalized MG (MGFA class II, III or IV)
[15]. A clinical diagnosis of MG had to be supported by
at least one of the following: a positive acetylcholine
receptor (AChR) antibody assay (AChR-Ab-positive),
positive intra-muscular neostigmine test or > 10% decre-
ment on 2-Hz repetitive nerve stimulation [18]. Subjects
were required not to have been treated with steroid-
sparing agents although they may have been prescribed
prednisone prior to inclusion.
For inclusion the severity of MG was such that it
resulted in functional disability with respect to the nor-
mal activities of daily living despite pyridostigmine ther-
apy so that immunosuppression was indicated. Subjects
with AChR-Ab-negative MG and thymoma-associated
MG were included if they fulfilled the above criteria and
thus required immunosuppressive therapy to control
myasthenic disease. Exclusions comprised those with
MG confined to the extraocular muscles or concomitant
illness such as uncontrolled thyroid disease or additional
polymyositis, or subjects with hepatitis B or HIV infec-
tions. Thymoma-MG subjects were stabilized on predni-
sone (± plasma exchange (P/E) or intravenous immune
globulin (IVIg)) and surgery scheduled to be performed
at the earliest possible time. Due to the concomitant
recruitment of generalized AChR-Ab-positive MG
patients for a thymectomy trial [19], all such patients
opting for this study had refused thymectomy. Poten-
tially child-bearing females were encouraged to use con-
traception. All patients were advised to refrain from
alcohol use [20].
Patients entered after written informed consent and
were randomized to either the AZA- or MTX-group
using a computer-generated random number sequence.
The principal investigator (PI)(JMH), patients and phar-
macists were unblinded, but the outcome assessors (AR,
KB and RR) remained blinded to the medication sub-
jects were receiving. During the consent process (pre-
randomization) it became evident that some subjects
could not be randomized as they were unable to afford
AZA. Due to limited study funding subjects received
their assigned treatment from either the state pharmacy
if indigent or from a private pharmacy if they had com-
prehensive medical insurance. However, participants
with partial health insurance, such as a hospital-plan,
were not eligible for free state-sponsored chronic medi-
cation and could not afford the more expensive AZA.
These subjects opted out of randomization but agreed
to follow study protocol taking MTX.
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The study was approved by the University of Cape
Town Health Science Faculty research ethics committee
(HSF-067/2005), registered with the South African
National Clinical Trials Registry (http://www.sanctr.gov.
za) DOH-27-0411-2436, and performed in compliance
with the Helsinki Declaration.
Treatment protocol
The dose of AZA approximated 2.5-3 mg/kg daily and
MTX 17.5 mg weekly. AZA was initiated at 50 mg daily
for 5 days followed by an immediate dose escalation to
approximately 2.5-3 mg/kg daily. AZA doses were
adjusted in subjects gaining weight. MTX was started at
7.5 mg weekly and escalated weekly by 2.5 mg until a
dose of 17.5 mg weekly. The MTX-group also received
5 mg folate for 5 days of every week (25 mg weekly)
excluding the MTX dosing day and the day thereafter.
Adverse events or toxicity were managed by reducing
MTX by 2.5 mg weekly and AZA doses by 25 mg daily.
Medications were scripted by the PI. Prednisone dos-
ing was adjusted according to protocol with the main
objective to obtain MMS as recorded by the blinded
assessors. Prednisone was initiated at 20 mg daily and
escalated by 5 mg weekly until either a dose of 60 mg
daily or 1 mg/kg was reached, or the patient reached
MMS on a lower dose. Patients in whom prednisone
had been initiated prior to study entry underwent a
similar prednisone dose escalation from the entry-level
dose. Hospitalized subjects underwent more rapid esca-
lations as required. Prednisone tapering (scripted by the
PI) was initiated at 5 mg decrements every month once
MMS was reached, or if prednisone-related side effects
intervened.
Pyridostigmine doses ranged between 180-360 mg daily
depending on symptoms. The dose required at the final
visit was noted. Vitamin D and Ca2+ supplements were
prescribed as is standard practice with prednisone.
Patients experiencing dyspepsia were prescribed hista-
mine-2 receptor antagonists (cimetidine) and, if symptoms
persisted, gastroscoscopy was performed and a proton-
pump inhibitor (omeprazole) initiated (standard care).
MG relapses were managed by increasing the dose of
prednisone or, if severe (impending MG crisis), additional
immune-suppression was administered such as P/E or
IVIg. If an unscheduled visit was required, the PI arranged
for staff unrelated to the study to assist in managing the
patient.
Visits were scheduled at baseline-, and 1-, 2-, 4- and 6-
months after study entry followed by 3-monthly visits for
2 years. At baseline the PI determined the duration of
symptoms prior to the diagnosis of MG and before study
entry. Pre-study cumulative daily prednisone dose and
duration were documented. Patients underwent a full
examination, laboratory screening including a complete
blood and differential count, urea and electrolytes, liver
transaminases, thyroid hormone, random serum glucose
and hepatitis B and HIV serological status. A chest X-ray
was performed followed by CT scanning of the mediasti-
num. Subject weight and blood pressure were measured
at each visit and the following laboratory tests were mon-
itored: blood counts, serum aspartate aminotransferase
(AST), alanine aminotransferase (ALT), gamma gluta-
myltransferase (GGT) and random glucose. An alcohol
intake questionnaire was completed at 6-monthly inter-
vals according to a 3-point scale; 0 did not drink, 1 did
some drinking (< 2 drinks per week), and 2 moderate
drinking (1 drink most days) [21].
At each visit the blinded assessors performed the MG-
ADL and the quantitative MG score [16]. The quantitative
MG score was used as described with a minor modifica-
tion related to hand grip. We anticipated a larger propor-
tion of older subjects and, therefore, adjusted the normal
values for the grip dynamometer from those expected for
50-year olds to normal ranges expected for 70-year old
participants as suggested by the manufacturer (T.K.K.
5401, Takei Scientific Instruments). The categories were
reduced by 66% to accommodate mild, moderate or severe
and the value for left-handed grip was 20% below the right
hand as recommended by Jaretzki et al. [16].
The PI reviewed medication related side effects and
laboratory values. The AZA or MTX doses were adjusted
if required. Laboratory toxicity was defined as white cell
count ≤3.0 x109/L, neutrophils ≤1.5 x109/L, or platelets
≤100 x109/L, or AST, ALT and GGT > 2-fold the upper
limit of normal.
Data management & Statistics
Outcomes related to prednisone dosing, quantitative MG
score and MG-ADL were analyzed in as per-protocol ana-
lysis in which data measurements of those who withdrew
were censored after the date on which they were no longer
on study medication. However, data of all subjects were
included in the denominator for proportionate outcomes
such as MMS and number of failures and “responders”. As
MG could relapse with prednisone weaning, only those
reaching sustained MMS defined as MMS until the end of
the study at 24 months, was deemed relevant. The first
treatment failure per patient was recorded in the propor-
tional analysis (per 6-month period).
The quantitative QMG scores were modeled as ordinal
variables and analyzed using a non-parametric test [22].
Quantitative MG score improvements from baseline (or
diagnosis whichever worse if P/E or IVIg were adminis-
tered after diagnosis but prior to baseline) were calculated
by subtracting the value from those at subsequent study
visits.
Patients were questioned at each visit regarding compli-
ance. With non-compliance, the recorded dose reflected
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that which was taken if different from the prescription
dose. Patients who missed an appointment were contacted
telephonically and the doses taken and MG functional
status (MG symptoms) were recorded.
Additional assessments included the number of epi-
sodes of worsening during the first year with worsening
defined as > 20% deterioration in the quantitative MG
score compared to baseline and the proportion of
“responders” defined as quantitative MG score improve-
ments of > 3.5 units from baseline [1,15].
For the statistical analysis, normally distributed data
were presented as means with standard deviations (SD)
and non- normally distributed data as median and inter-
quartile ranges (IQR). The Student t-test, the Mann-
Whitney test and the c2 test (or Fisher exact test) were
used to compare data, as appropriate. All analyses were
two-sided and a p-value < 0.05 was considered signifi-
cant. Statistical analyses were done using STATISTICA 9
(Statsoft®).
Results
The study was conducted between 2005 and 2010 and due
to slow recruitment it was halted after five years. Eight eli-
gible subjects with AChR-Ab-positive generalized MG
were either recruited to a thymectomy trial (n = 5) [19] or
declined study participation (n = 3) as they lived too far
from the study site. Thirty-one subjects entered the study.
Twenty-four subjects were randomized to either MTX
(n = 11) or AZA (n = 13). The residual 7 subjects were
willing to follow study protocol but were not randomized
either because they could not afford AZA if potentially
randomized to that group (n = 5) and therefore included
into the MTX-group, or because they opted for standard
of care therapy with AZA (n = 2) (Figure 1).
The MG subtypes were similar (Table 1). Four of
seven AChR-Ab- negative cases were screened for
MuSK antibodies and one was positive. The symptom
duration prior to a diagnosis (and treatment) of MG
were similar in the two groups; two patients, one in
each group, had symptom duration of almost four years.
Seven participants (AZA = 3; MTX = 4) had not
received any prednisone prior to study entry. The
remaining subjects had received prednisone since their
MG diagnosis within the previous six months, but the
prednisone doses and treatment duration were similar
between the two groups (Table 1). All thymoma-MG
patients except two, were stabilized on prednisone (± P/
E or IVIg) and surgery performed prior to study entry.
One patient, who was diagnosed with thymoma on CT
chest after study entry, could only undergo thymomect-
omy four months later and one patient persistently
refused surgery throughout the study period. None of
the non-thymoma MG patients underwent thymectomy
(see above).
Baseline values between the AZA- and MTX-group
were similar including the duration of MG symptoms
prior to study entry or MG diagnosis (results not shown,
p = 0.51) and the proportion on prednisone, as well as
the cumulative prednisone exposure prior to baseline
(Table 1). The baseline bodyweight, MGFA severity
grade, quantitative MG scores, and proportions requiring
pre-study IVIg or P/E were similar (Table 1). Seven
patients (AZA = 3; MTX = 4) required hospitalization at
the time of diagnosis.
Prednisone doses were not significantly different
between the AZA and MTX groups throughout the
study except at months 10 (p = 0.047) and month 12 (p
= 0.039) when the average daily doses by month were
significantly lower (2-sided) in the MTX-group; mean
difference (Δ) between MTX and AZA (MTX-AZA) at
month 10 = 10.21 mg; 95% confidence interval (CI)
0.12; 20.21; mean Δ month 12 = 10.89 mg; 95% CI 0.58;
21.21. Months 11, 13 and 14 showed a trend (p = 0.078)
towards lower doses of prednisone in the MTX-group
(Figure 2). The average daily prednisone dose per kilo-
gram bodyweight at month 12 was also lower in the
MTX-group being on average 0.15 mg/kg prednisone
(SD ± 0.08) daily as compared with that in the AZA-
group of 0.31 mg/kg (SD ± 0.22)(mean Δ 0.16; 95% CI
0.29; 0.03; p = 0.019).
The quantitative MG scores over 2-years of study did
not differ between the two groups and neither did the
absolute change at 6-montly intervals (p = 0.40) (Table 2).
Figure 1 An outline of subject participation during the study. *
1 patient died of unrelated causes at 12.5 months (see text).
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Although the study examinations were scheduled at the
same time and weekday throughout the study period, the
timing of the preceding pyridostigmine dose in relation to
each examination, was not documented. Similar propor-
tions of subjects in each group reached sustained MMS
(AZA n = 7; MTX n = 9; p = 0.83) (Table 2) with a med-
ian time to sustained MMS of 12.0 months (IQR 8.0; 16.0)
in the AZA-group and 10.5 months (IQR 5.0; 16.5) in the
MTX-group (p = 0.97). The proportions of treatment
responders were similar in both groups (data not shown).
Intolerable diarrhoea (AZA n = 1; MTX n = 1), hear-
ing loss and acne (AZA n = 1) and loss of appetite
(MTX n = 1) resulted in study withdrawals during the
first six months (Table 2). MG relapses requiring hospi-
talization (with or without additional IVIg or P/E)
occurred in both groups within six months and in two
AZA-patients between 7-12 months. The time to first
treatment failure was similar in the two groups (p =
0.99)(data not shown).
Table 1 Demographics and baseline characteristics of participants
Azathioprine Methotrexate P value
Patients, n (Females/Males) 15 (9/6) 16 (10/6) 0.45a
Age (years), mean ± SD 42.7 ± 16.8 47.9 ± 14.8 0.37b
Weight (kg), mean ± SD 77.1 ± 21.2 76.9 ± 23.0 0.98b
Type of MG, n (%) 0.83a
AChR-Ab-positive 9 (60) 10 (62)
Thymoma 2 (13) 3 (19)
AChR-Ab-negative 4 (27) 3 (19)*
Pre-study characteristics
Symptom duration (months), mean ± SD 10.3 ± 10.6 7.5 ± 13.0 0.51b
Symptom duration (months), median (IQR) 6.0 (1.5; 15.0) 4.8 (2.3; 8.0)
Patients on prednisone pre-study, n (%) 12 (80) 12 (75) 0.74a
Prednisone duration (months), mean ± SD 1.5 ± 1.8 1.3 ± 1.1 0.63b
Cumulative prednisone (mg), mean ± SD 1170 ± 1768 1032 ± 1117 0.79b
MGFA severity at presentation, n
Grade 2a/2b 2/0 2/2
Grade 3a/3b 2/3 1/5
Grade 4a/4b/5 1/6/1 0/4/2
Pre-study P/E or IVIg, n 1 3




Thyroid disease on stable replacement therapy 1 2
Other autoimmune disease** 1 1
Other disease # 3 4
SD- standard deviation; IQR- interquartile range; AChR-Ab-positive - refers to AChR antibody positive non-thymoma MG; *1 patient MuSK-antibody positive.
NIDDM refers to non-insulin dependent diabetes mellitus. Only thymoma-MG patients underwent thymomectomies- see text.
**vitiligo & pernicious anaemia.
# Other disease refers to asthma, idiopathic seizures (n = 1), peptic ulcer disease (n = 1), obesity with polycystic ovaries (n = 1), hypercholesteremia (n = 1),
benign prostatic hypertrophy (n = 1); gluten sensitive enteropathy (n = 1).
a c2 test. b t-test.
Figure 2 Average daily prednisone dose by month of those
remaining on their assigned steroid-sparing agent. Prednisone
dose refers to average mg per day. Error bars ± standard error of
the mean. *p = 0.078; **10 months p = 0.047 and **12 months
p = 0.039.
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One patient (70-year old male) suffered a fatal myo-
cardial infarction, an event judged to be unrelated to
either MG or study medications (Table 2). This patient
had several pre-morbid risk factors for ischemic heart
disease and had been randomized to AZA. He died at
12.5 months into the study during which time his MG
had improved consistently.
Adverse events recorded amongst both groups were
similar apart from a preponderance of gastrointestinal
events amongst the MTX-group and more anxiety and
moodiness amongst the AZA-group (Table 3). The body-
weight of the subjects determined at baseline (Table 1)
and subsequently at the 3-monthly visits (data not
shown), were similar in the two groups (p = 0.40). No
patient withdrew due to abnormal liver functions (Table
4). Elevated liver transaminases was the most frequent
reason for MTX dose adjustments (3/16; 19%) to 15 mg
(n = 2) and 12.5 mg weekly (n = 1). Two subjects who
developed insulin-dependent diabetes did not show
abnormalities of liver enzymes. Most patients reported
either using no or occasional alcohol. Three subjects
took moderate alcohol without any alterations in liver
functions.
At the end of the study, incorporating dose adjust-
ments due to adverse events (Table 4), the final average
AZA dose was 2.23 mg/kg daily (SD ± 0.74; n = 11) and
the final MTX dose was 16.73 mg weekly (SD ± 2.14; n =
14). The final mean pyridostigmine dose did not differ
between the AZA-group (176 mg; SD ± 136) and MTX-
group (150 mg; SD ± 103), p = 0.56. By the end of the
study, three AZA- and four MTX-subjects had comple-
tely weaned pyridostigmine and four in each group had
completely weaned prednisone.
Discussion
We present the results of the first controlled trial using
methotrexate in myasthenia gravis. In this single-blinded
study involving recently diagnosed generalized MG sub-
jects, we show that MTX has an onset of steroid-sparing
efficacy from 10 to 12 months in subjects using an average
dose of 17 mg weekly which is earlier than that of AZA.
Two previous trials studying AZA, the comparator, found
the efficacy as steroid-sparing immunosuppressant to
become apparent between 15 to 18 months [1,3].
MG has a fluctuating disease course and it has been
suggested that a more robust measure of treatment effi-
cacy would be sustained minimal manifestation status
(MMS) as opposed to transient MMS that may be fol-
lowed by deterioration [1]. Both treatment groups in this
study achieved similar proportions of participants with
sustained MMS after similar treatment periods (Table 2).
The responsiveness to treatment was also similar in both
groups as measured by the improvement in quantitative
MG score compared to baseline [15]. These outcomes
are to be expected with adherence to the treatment pro-
tocol in this study as MMS was achieved by adjusting
doses of prednisone in addition to the steroid-sparing
effects of AZA or MTX. Steroid-sparer efficacy is
regarded as being inversely related to the dose of predni-
sone required to maintain MMS in each group. From
Table 2 Treatment outcomes and failures at 6-monthly intervals
Baseline 6 months 12 months 18 months 24 months
QMGS
AZA, median (IQR) 20.0 (11; 24) 7.0 (5; 8) 7.0 (5; 13) 5.0 (3; 10) 6.0 (3; 8)
MTX, median (IQR) 19.5 (16; 24) 7.5 (4; 11) 7.5 (6; 9) 8.0 (6; 10) 8.0 (6; 9)
MG-ADL
AZA, median (IQR) 6.0 (3; 8) 3.0 (0; 5) 2.0 (0; 6) 1.0 (0; 1) 0 (0; 1)
MTX, median (IQR) 7.5 (4; 10) 1.0 (0; 5) 1.0 (0; 3) 0.5 (0; 1) 0 (0; 1)
MMS*
AZA, n (%) 2/15 (13) 4/15 (27) 5/15 (33) 7/15 (53)
MTX, n (%) 3/16 (19) 5/16 (31) 5/16 (33) 9/16 (56)
Period in months 0-6 6-12 12-18 18-24
Treatment failures, n
A/E withdrawals: AZA 2/15 2/13** - -
A/E withdrawals: MTX 2/16 - - -
MG relapses: AZA 4/15# 2/13## - -
MG relapses: MTX 3/16# 0/14 - -
p > 0.05 for all comparisons. QMGS refers to quantitative MG score.
* MMS or minimal manifestation status refers to a) cumulative proportions in an intention to treat analysis and b) only to subjects with MMS maintained until the
end of the study.
A/E refers to adverse events. ** includes 1 serious A/E: died of myocardial infarction.
# 2 subjects in each group received either a course of plasma exchange (P/E) or IVIg.
## one subject received P/E.
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Table 2 it is evident that most improvement occurred in
the first 6 months and was likely attributable to a steroid
effect.
Longitudinal observation of MG subjects has indicated
that approximately 10-15% of patients may go into sponta-
neous remission, usually after several years [23]. In our
study the proportion of subjects in MMS (i.e. those with-
out MG symptoms) was at least 25% in both groups at
12 months, escalating to more than 50% in both groups by
24 months (Table 2). Also, the majority of subjects had
either moderate or severe disease at study entry with simi-
lar disease severity and duration in both treatment groups.
It is therefore unlikely that spontaneous remissions con-
tributed significantly to the outcomes investigated.
Study withdrawal as a result of drug intolerance was
as frequent amongst those taking MTX as AZA (13%),
Table 3 Adverse events experienced since study entry and the action taken





CVS Hypertension 2 4 Resolved on antihypertensives
Palpitations 2 0 Resolved- no action
Pedal edema 1 2 1 -required diuretics
Digestive Diarrhoea 2 1 2- resolve on study withdrawal
1- resolve no action
Dyspepsia 1 7 Resolve on H2-R antagonist/PPI*
Excessive weight gain** 7 8 ↓ prednisone if accompanied by other AEs
Gastric ulcer 0 1 Resolved on medical management
Increased appetite 1 0 No action
Endocrine Diabetes requiring insulin 1 1 Controlled on insulin
NIDM new 3 1 Controlled on hypoglycemics & ↓ prednisone
Blurred vision-lens edema 0 1 Resolve on ↓ prednisone
Moon face 1 1 Improved on ↓ prednisone
Mouth ulcers 0 2 Resolve- no dose change
Nervous Anxiety, insomnia, moody 5 0 Controlled on amitryptaline & ↓ prednisone
Cramps in legs 3 2 Controlled on K+ supplements
Dysesthesiae in feet 0 1 Improved on ↓ prednisone
Fatigue/asthenia 0 1 No action
Headache 0 1 Resolve -no action
Hearing loss 1 0 Resolve on study withdrawal
Tremors 0 2 Intermittent; no action
Respiratory Pneumonia 1 0 Intravenous antibiotics
Skeletal Arthralgia 1 2 Intermittent; no action
Skin Acne/erythema/hirsutism 1 1 Resolve on prednisone reduction/withdrawal
Fungal infection 1 2 Resolve on topical antifungals & ↓ prednisone
Hidradenitis suppurativa 1 0 Oral antibiotics with incision drainage
CVS refers to cardiovascular; AZA- azathioprine; MTX- methotrexate.
* H2-R antagonist (histamine-2 receptor antagonist (cimetidine n = 5) or proton pump inhibitor (omeprazole n = 2))
** weight gain during the study of more than 10% of body weight at baseline visit.
Table 4 Laboratory adverse events according to treatment groups, and action taken
AZA n = 4/15 MTX
N = 3/16
Amylase > 2 × ULN 1 0 Resolved on dose reduction
AST > 2 × ULN 1 1 Resolved on dose reduction
ALT > 2 × ULN 2 1 1 resolved on dose reduction; 2 no action & stable
ALT > 3 × ULN 0 1 Improved on dose reduction- stable
GGT ≥2 × ULN 1 1 1 resolved on dose reduction; 1 no action & stable/resolved
AZA- azathioprine; MTX- methotrexate. ULN refers to upper limit of normal.
ALT refers to alanine aminotransferase, normal range 5-40 U/L, AST to aspartate amintransferase, normal 5-40 U/L, GGT to gamma-glutamyl transpeptidase,
normal 0-35 U/l.
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and comparable to that observed in a previous study
(11%) when these two agents were compared in patients
with Crohn’s disease, although only for six months [14].
A 48-week comparison between the two agents in RA
found more frequent AZA withdrawals [11]. In our
study, MTX was well tolerated with few patients requir-
ing dose adjustments to manage raised transaminase
levels, which did not necessarily occur in individuals
with an increased body mass index as previously
reported [24]. The low incidence of liver toxicity may
have been due to folate supplementation [25,26]. In this
study 25 mg of folate was supplemented every week
although previous reports show (a) no differences
between 5 mg folate weekly and higher doses in redu-
cing MTX-toxicity and (b) that higher doses of folate
may result in an individual requiring higher MTX doses
to achieve efficacy [25-27]. Although we advised against
consuming more than one alcoholic drink per week,
others have allowed moderate alcohol intake without
this apparently influencing transaminase levels in their
subjects [25].
MTX has anti-inflammatory, anti-proliferative and
immune-modulatory activities some of which are due to
the cellular induction of adenosine and consequent sup-
pression of NF-KB activation, a key transcription factor
(reviewed in [28]). These effects may explain the early
(within 3-6 weeks) radiographic improvements observed
in MTX-treated RA subjects [12]. MTX has also been
shown to have immunosuppressive effects including apop-
tosis and clonal deletion of activated T cells, an inhibitory
effect on proliferating cells [27] including B cells, a reduc-
tion in pro-inflammatory cytokine production by T cells
and macrophages [29] and CD95-dependant apoptosis of
activated memory T cells [27]. In RA, accumulated data
suggest that strategies to use MTX earlier with faster dose
escalations and intensive regimens of 17-20 mg/week
showed control in disease activity within three to four
months (reviewed in [6,30]). The optimal initiation dosing
strategy recommends starting at 15 mg weekly unless the
patient is elderly or bodyweight is below 50 kg in which
case some would start at 7.5 mg weekly [6,21].
A major limitation of our study is its small size with
only 24 of 31 participants undergoing randomization. As
we recruited substantially fewer subjects than we antici-
pated, the possibility exists that we have falsely accepted
MTX treatment as equivalent to AZA when it is inferior
(type 1 error). Nevertheless, our results do suggest that
MTX shows an earlier onset of steroid-sparing efficacy
than AZA. This study represents the “real-life” situation
in that a spectrum of patients with generalized MG
were recruited including AChR-Ab-negative and thy-
moma-associated variants: two less prevalent MG sub-
groups often associated with severe disease requiring
immunosuppression [7,9,10,31,32]. Another limitation of
our study is that we did not systematically examine
MuSK antibody status of all our AChR-Ab-negative sub-
jects. MuSK-positive MG can be difficult to manage
with immunesuppressants [10]. We did identify one
MuSK-positive subject who was randomized to MTX,
required and responded to plasma exchange at study
entry, and maintained a “responder” status throughout
the 2-year of study.
Due to a concurrent study assessing the role of thy-
mectomy in MG [19] in which AChR-Ab-positive MG
subjects amenable to possible thymectomy were recruited
to that study, all the patients recruited into this study had
refused thymectomy and consequently this was not per-
formed. In this manner bias might have been introduced.
However, < 20% of this study population had mild gener-
alized (MGFA Grade 2) disease. Another source of
potential bias was the fact that socioeconomic status pre-
vented five subjects from being randomly assigned to
either treatment group. Other limitations, due to limited
funding, included patients being unblinded to the study
medications and prednisone dosing being captured by
intended script dosing and verified by patient recall at
the following visit. The latter may have resulted in minor
inaccuracies in daily prednisone dosing.
Conclusions
In a study population that is representative of that seen
in a MG clinic, we present class III evidence [33] that
an average methotrexate dose of 17 mg weekly is an
effective steroid-sparer in generalized MG evident from
10-months of treatment initiation. Our data suggests
that in addition to an earlier onset of action, methotrex-
ate has similar efficacy and tolerability to azathioprine in
recently diagnosed generalized MG and may be the drug
of choice in financially constrained health systems.
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